Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR.
Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Curr Opin Pulm Med. 2023 May 1;29(3):174-183. doi: 10.1097/MCP.0000000000000953. Epub 2023 Mar 14.
COVID-19 pandemic has caused more than 6.6 million deaths globally. Tremendous efforts have been committed for the development of new and repurposed drugs for the treatment of COVID-19. Although different international and national guidelines share consensus in the management of COVID-19 disease with different levels of severity, new challenges have emerged, steering the need for ongoing research in advancing the clinical management of COVID-19.
This review focuses on recent data from randomized trials and postmarketing real-world evidence for the treatment of mild to moderate disease in the outpatient setting and patients hospitalized for COVID-19 with varying level of severity. Relevant data for treatment of the latest omicron sub-variants in people who received vaccination are presented. Challenges in special populations, including immunocompromised hosts, patients with renal failure and pregnant women, are also discussed.
Treatment of COVID-19 should be personalized according to host characteristics, degree of severity and available treatment options.
COVID-19 大流行已在全球造成超过 660 万人死亡。为治疗 COVID-19，人们投入了巨大的努力来开发新的和已有的药物。尽管不同的国际和国家指南在管理不同严重程度的 COVID-19 疾病方面存在共识，但新的挑战不断出现，需要不断研究以推进 COVID-19 的临床管理。
本综述重点关注随机试验和上市后真实世界证据中的最新数据，这些数据涉及轻至中度疾病在门诊环境中的治疗，以及不同严重程度住院的 COVID-19 患者。还介绍了针对接种疫苗人群中最新的 omicron 亚变体的治疗相关数据。还讨论了特殊人群（包括免疫功能低下的宿主、肾衰竭和孕妇）的挑战。
COVID-19 的治疗应根据宿主特征、严重程度和可用的治疗选择进行个体化。
